Delivery Order SPE2DB22D2206-SPE2DB25FJD74
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Taltz 80 mg/ml autoinjectors with a ceiling value of $4,197.10. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, reflecting a short fulfillment timeline for this pharmaceutical product. The contract utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of TALTZ 80 mg/ml autoinjector medication, valued at $72,800.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract carries an ultimate completion date of August 1, 2025, and performance will be executed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a $46,054.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Taltz 80 mg/mL auto-injector (2-pack) pharmaceutical product. The contract, which is set to be completed by August 1, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This competitively awarded delivery order represents a continuation of AmerisourceBergen's ongoing role as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a $31,833.56 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/mL auto-injector (2-pack) pharmaceutical products, with an ultimate completion date of July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml auto-injector medication with a ceiling value of $3,698.27. This non-set-aside, competitively awarded contract employs firm fixed price pricing and is scheduled for completion by July 31, 2025. The delivery order serves as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of TALTZ 80 mg/ml auto-injector two-packs with a ceiling value of $8,391.13. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- This delivery order, valued at $4,980.91, was awarded on July 29, 2025, to AmerisourceBergen Drug Corp for the supply of TALTZ 80 mg/ml auto-injector three-packs. The contract is funded by the Defense Logistics Agency's Medical Supply Chain division and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This award represents a firm fixed price delivery order with no set-aside designation, indicating it...
- The Defense Logistics Agency awarded a $4,083.21 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml auto-injector (2-pack) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order utilizes firm fixed-price pricing and is fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania. The award represents a single-line pharmaceutical procurement supporting federal medical supply needs, likely for military or veteran healthcare...
- The Defense Logistics Agency awarded a $11,664.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml autoinjector on July 31, 2025, with completion due August 1, 2025. This non-set-aside contract represents a small-value pharmaceutical supply delivery executed through AmerisourceBergen's existing federal contract vehicle with DLA. The award leverages the contractor's established relationship with the Defense Logistics Agency Medical Supply Chain, which has...
- The Defense Logistics Agency (DLA) awarded a $9,973.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of TALTZ 80 mg/mL auto-injector (2-pack) pharmaceutical product, with an ultimate completion date of July 30, 2025. This is a non-set-aside award issued on July 29, 2025, with fulfillment based at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJD74Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TALTZ 80 mg/ml auto-injector (2-pack) with a ceiling value of $9,029.13 under a firm fixed-price contract type. This award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999.9 million through December 2026. The contract was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting military and veteran healthcare systems. The delivery order is scheduled for ultimate completion by July 31, 2025, with performance taking place at AmerisourceBergen's Conshohocken, PA facility. This award reflects the company's established role as a prime vendor within the DLA's pharmaceutical supply chain, delivering a wide range of brand-name and generic medications, specialty drugs, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency and other federal healthcare systems. The rapid completion timeline indicates this represents a time-sensitive pharmaceutical supply requirement within the military healthcare network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 7/30/25 |